- The P-III RESET study involves assessing of Rivipansel (IV) vs PBO in 345 patients in a ratio (1:1) with SCD who were hospitalized for a VOC and required treatment with IV opioids aged ≥ 6yrs.
- The P-III RESET (B5201002) study results demonstrated that it did not meet its 1EPs of time to readiness-for-discharge and 2EPs of time-to-discharge, cumulative IV opioid consumption, and time to discontinuation of IV opioids
- Rivipansel is a glycomimetic therapy, acts as a pan-selectin antagonist and binds to E-, P- and L-selectin, being evaluated for VOC in patients with SCD. In 2011, Pfizer signs a WW license agreement with GlycoMimetics to develop & commercialize rivipansel
Click here to read full press release/ article | Ref: Pfizer | Image: Stat